Kristen Williams, serving as the Chief Administrative Officer for Pacira BioSciences, Inc. (NASDAQ: PCRX), has executed a series of significant stock transactions, according to recent filings with the Securities and Exchange Commission. The disclosures highlight both planned sales and mandatory share withholdings, reflecting standard corporate governance procedures while underscoring the executive's ongoing relationship with the company's equity.
On June 4, 2026, Ms. Williams disposed of 10,259 shares of common stock at a price of $22.27 per share. This transaction was carried out under the framework of a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged stock sales. The plan itself was adopted earlier, on September 10, 2025, establishing a structured approach to her equity management. The proceeds from this specific sale amounted to $228,467.
In a separate transaction on June 3, 2026, Ms. Williams experienced a disposition of 8,528 shares. These shares were not voluntarily sold but were withheld by Pacira BioSciences to satisfy tax withholding obligations associated with the vesting of a restricted stock unit award. This involuntary transfer was valued at $190,344, calculated at a price of $22.32 per share. Following these combined actions, Ms. Williams retains a direct holding of 167,062 shares of Pacira BioSciences common stock.
These executive movements occur against a backdrop of strong financial performance for Pacira BioSciences. The company reported a robust first quarter for 2026, with earnings per share reaching $0.60, surpassing the forecast of $0.56. Revenue for the quarter also exceeded expectations, coming in at $177 million compared to the projected $172.46 million. The company announced 2025 total revenue of $726.4 million with GAAP gross margins of 79.4%. In addition, EXPAREL revenue for the first quarter of 2026 was $143.3 million, marking a 5% increase year-over-year, while ZILRETTA revenue rose by 15% to $26.8 million, and iovera revenue grew by 21% to $6.2 million.
Corporate governance and shareholder engagement remain active topics for Pacira BioSciences. The company is urging shareholders to support its board nominees at the upcoming annual meeting on June 9, 2026. Meanwhile, DOMA Perpetual Capital Management, holding 7.5% of the company, has nominated three directors to the board, citing concerns over litigation strategy and financial performance. Additionally, a recent study presented at the ISPOR 2026 Annual Meeting highlighted the use of EXPAREL in reducing opioid consumption following outpatient total shoulder arthroplasty in Medicare Advantage patients. These developments reflect ongoing strategic and operational activities within Pacira BioSciences.
The intersection of executive equity activity and corporate performance provides insight into the operational dynamics of Pacira BioSciences. The structured nature of the sales, governed by a pre-established trading plan, indicates adherence to regulatory frameworks for insider transactions. Concurrently, the strong financial results and product revenue growth suggest continued operational momentum in the biopharmaceutical sector. The ongoing governance discussions, including external director nominations, highlight the importance of shareholder alignment and strategic oversight in the company's current phase.